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Abstract
Background: To assess the performance of plasma neurofilament light (NfL) and phosphorylated tau 181 (p-
tau181) to inform about cerebral Alzheimer’s disease (AD) pathology and predict clinical progression in a memory
clinic setting.
Methods: Plasma NfL and p-tau181, along with established cerebrospinal fluid (CSF) biomarkers of AD pathology,
were measured in participants with normal cognition (CN) and memory clinic patients with cognitive impairment
(mild cognitive impairment and dementia, CI). Clinical and neuropsychological assessments were performed at
inclusion and follow-up visits at 18 and 36 months. Multivariate analysis assessed associations of plasma NfL and p-
tau181 levels with AD, single CSF biomarkers, hippocampal volume, and clinical measures of disease progression.
Results: Plasma NfL levels were higher in CN participants with an AD CSF profile (defined by a CSF p-tau181/Aβ1–
42 > 0.0779) as compared with CN non-AD, while p-tau181 plasma levels were higher in CI patients with AD. Plasma
NfL levels correlated with CSF tau and p-tau181 in CN, and with CSF tau in CI patients. Plasma p-tau181 correlated
with CSF p-tau181 in CN and with CSF tau, p-tau181, Aβ1–42, and Aβ1–42/Aβ1–40 in CI participants. Compared with a
reference model, adding plasma p-tau181 improved the prediction of AD in CI patients while adding NfL did not.
Adding p-tau181, but not NfL levels, to a reference model improved prediction of cognitive decline in CI
participants.
Conclusion: Plasma NfL indicates neurodegeneration while plasma p-tau181 levels can serve as a biomarker of
cerebral AD pathology and cognitive decline. Their predictive performance depends on the presence of cognitive
impairment.
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Background
In vivo detection of the cerebral pathophysiological pro-
cesses of Alzheimer’s disease (AD) is key to accurate
diagnosis and appropriate care. Cerebrospinal fluid
(CSF) and positron tomography biomarkers of amyloid
and tau accurately detect AD, but are of limited use in
clinical practice due to the associated costs, invasiveness,
or non-availability of the tools needed [1]. Non-invasive
blood-based biomarkers could provide an attractive al-
ternative, allowing to identify patients that may benefit
from further, more invasive and/or costly diagnosis, or
for recruitment and monitoring of participants in clinical
trials [2].
Neurofilament light (NfL) protein and tau phosphory-
lated at threonine 181 (p-tau181) are promising candi-
dates for blood-based biomarkers of AD. NfL blood level
has been proposed as a biomarker for axonal damage
and neuronal injury [2] and has been found to be in-
creased in clinically diagnosed AD compared with
healthy controls [3–6]. It also has been associated with
cognitive decline in participants with normal cognition
[7], and neurodegeneration across neurodegenerative
diseases [8]. Plasma p-tau181 has been recently reported
to be increased in both clinically diagnosed [9] and bio-
marker confirmed AD dementia [10], and to correlate
with CSF tau levels and amyloid PET measurements [11,
12]. Furthermore, it may predict disease progression and
cognitive decline in cognitively unimpaired participants
and MCI patients [13].
Here, our aim was to test the ability of plasma NfL
and plasma p-tau181 levels, or the combination thereof,
to serve as blood-based biomarkers for the diagnosis of




Two hundred and twenty-one individuals aged 49 to 88
years were recruited at the memory clinic of the Depart-
ment of Psychiatry and the Department of Clinical Neu-
rosciences at the University Hospital of Lausanne,
Switzerland into an AD biomarker discovery study co-
hort between 2014 and 2018. Participants were recruited
among memory clinic patients and through advertising
and word-of-mouth for healthy participants. All partici-
pants underwent a comprehensive clinical evaluation
and neuropsychological assessment as previously de-
scribed [14]. Briefly, a comprehensive test battery along
with standard questionnaires were used to determine the
Clinical Dementia Rating (CDR [15]), CDR sum of boxes
(CDRSoB), Mini-Mental State (MMSE), and to verify
subgroup inclusion criteria. The cognitive impairment
group (CI) included patients with the clinical diagnoses
of mild cognitive impairment (MCI [16], n = 56) or
dementia (n = 71) and a CDR score ≥ 0.5 [14]. Patients
with major psychiatric or neurological disorders, sub-
stance abuse, or severe or unstable physical illness that
could affect cognition were excluded. Cognitively normal
participants (CN) were free of relevant acute psychiatric
or neurologic affection, had neither current cognitive
impairment nor a history of it, and had a CDR = 0. MRI
and CT scans were performed in all participants and
used to exclude individuals with major cerebral patholo-
gies possibly interfering with the cognitive performance.
Clinical and neuropsychological evaluations were re-
peated after roughly 18 and 36months, during follow-up
visits using the same study protocol.
Blood and cerebrospinal fluid collection
Venous and lumbar punctures were performed after an
overnight fast. Ten to twelve milliliters of CSF was col-
lected for analysis, centrifuged at 4 °C, immediately ali-
quoted, and frozen at − 80 °C until assayed, as previously
described [17].
CSF AD biomarkers, albumin quotient, and
Apolipoprotein E genotype
CSF β-amyloid 1–42 peptide (Aβ1–42), total-tau (tau),
and tau phosphorylated at threonine 181 (p-tau181) con-
centrations were measured using commercially available
ELISA kits (Fujirebio Europe, Gent, Belgium). Addition-
ally, the concentrations of Aβ1–42 and Aβ1–40 were mea-
sured with immunoassays from IBL International
(Hamburg, Germany) according to the manufacturer’s
protocols. The albumin CSF/serum quotient (QAlb) as a
marker of blood-CSF barrier function along with the
apolipoprotein E (APOE) genotype were determined as
previously described [18].
Plasma biomarkers
NfL concentrations were measured using the NF-light™
kit on a Single molecule array (Simoa) HD-X Analyzer
(Quanterix, Billerica, MA, USA), following the recom-
mendations by the manufacturer. Plasma p-tau181 levels
were measured using an in house Simoa assay as previ-
ously described [10]. Briefly, an AT270 mouse monoclo-
nal antibody (MN1050; Invitrogen, Waltham, MA, USA)
was coupled to paramagnetic beads (103,207; Quanterix)
and used for capture. As the detector, we used the anti-
tau mouse monoclonal antibody Tau12 (806,502; BioLe-
gend, San Diego, CA, USA), conjugated to biotin
(A3959; Thermo Fisher Scientific, Waltham, MA, USA),
while GSK-3β phosphorylated full-length recombinant
tau441 (TO8–50FN; SignalChem, Vancouver, BC,
Canada) was used as calibrator. Fluorescent signals were
converted to average enzyme per bead numbers as de-
scribed [19], and specimen concentrations extrapolated
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from four-parametric logistic curves generated with
known calibrator concentrations.
Hippocampal volume measurements
All participants underwent a magnetic resonance im-
aging scan at inclusion on a 3 T MRI system (MAGN
ETOM Prismafit, Siemens Healthcare, Erlangen,
Germany) with a 32-channel head coil. Acquisitions
followed the ADNI2 MRI protocol (http://adni.loni.usc.
edu/methods/documents/). Images were segmented with
the MorphoBox prototype [20], and both overall image
[21] and segmentation quality were automatically
assessed [20]. Here we used regional volumetric data
normalized by total intracranial volume (defined as the
sum of gray matter, white matter and CSF) to determine
relative hippocampal volume.
Data and statistical analysis
Before analysis, outliers for CSF and plasma biomarker
levels (i.e., data points that exceeded the cut-off value of
mean ± 3 × SD; 12 out of 205 for plasma NfL and 8 out
201 for plasma p-tau181 levels were concerned by this
change, accounting for less than 3% of all data points)
were replaced by the cut-off value to minimize quantifica-
tion errors. All participants within the CN and CI sub-
groups were further classified as AD or non-AD according
to the presence or absence of an AD CSF profile. An AD
CSF profile was defined by a CSF p-tau181/Aβ1–42 ratio >
0.0779. This cut-off value was internally established as
previously described [17]. Briefly, this value was deter-
mined using center data obtained from one hundred and
twenty participants and was the value that optimized
group separation based on the Youden index in this sam-
ple and was in line with previous publications [22]. Bio-
marker and cognitive change data were log-transformed
prior to correlation and regression analyses to approach
Gaussian distribution. Subgroups within the cohort were
compared using Students’ two-tailed t-test for continuous
variables and chi-square tests for categorical variables.
Data are given as mean ± standard-deviation. Correlations
between CSF AD biomarkers and plasma biomarkers were
assessed using Spearman’s rho. Benjamini-Hochberg cor-
rection of P-value for multiple testing was applied for all
analyses using a false-discovery rate of 0.1. Potential col-
linearity of the explanatory variables used in the regression
modeling was tested with variance inflation factor (VIF).
No variable entered in these models had VIF above 1.5;
thus, the absence of multicollinearity was assumed. Statis-
tical data analysis was performed with IBM SPSS Statistics
software version 25.
Statistical modeling
To assess the association of plasma NfL and plasma
p-tau181 with the presence of AD pathology, we used
logistic regression models with occurrence of AD as a
dependent variable while entering both plasma
markers as independent variables. We explored the
effects of the following covariates: age, sex, years of
education, and APOE ε4 status. Best predictive
models were obtained using a backwards selection
method where variables with a likelihood-ratio statis-
tic probability > 0.1 were removed iteratively. A refer-
ence model for prediction of AD using only age, sex,
years of education, and with or without APOE ε4 sta-
tus was constructed using logistic regression in the
CN and CI subgroups individually. We then added ei-
ther plasma NfL levels or plasma p-tau181 levels, or
both to this model. Predictive performance was
assessed by computing a ROC curve and area under
the curve (AUC) for these models and were compared
using the DeLong method. Estimation of cut points
for p-tau181 for the prediction of a CSF AD profile
was done using R software (cutpointr package) and
selecting the cutoff level that maximized the predic-
tion accuracy of logistic regression models in CI
participants.
Associations of plasma NfL and plasma p-tau181 with
cognitive measurement changes were first assessed with
linear regression models using CDRSoB or MMSE
changes at the last follow-up visit as a dependent vari-
able while entering both plasma markers as independent
variables. We explored the effects of the following covar-
iates: age, sex, years of education and APOE ε4 status,
and baseline MMSE or CDRSoB scores, and time to
follow-up. Best predictive models were obtained using a
backwards selection method, where variables with a F-
score statistic probability > 0.1 and the smallest correl-
ation with the dependent variables were removed itera-
tively. In parallel, reference models for the prediction of
clinical disease progression (CDRSoB change ≥1) or de-
cline in global cognition (MMSE change ≥ − 2) using the
above covariates were constructed in the CN and CI
subgroups separately. We then added either plasma NfL
levels or plasma p-tau181 levels, or both, to these
models. Predictive performance was assessed using ROC
and AUC values of models compared using the DeLong
method as above.
Goodness-of-fit of logistic regression models was
assessed using the Hosmer-Lemeshow test. None of the
above models displayed a Hosmer-Lemeshow chi-
squared value yielding a P-value < 0.05 and therefore
none were rejected.
Data availability
The datasets used and/or analyzed during the current
study are available from the corresponding author upon
reasonable request.
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Results
Cohort description
Subject characteristics and cognitive assessments average
by group comparisons, based on cognitive status at base-
line together with AD CSF biomarkers, biochemical
measures, and plasma NfL and p-tau181 levels, are
shown in Table 1. Longitudinal clinical data from at least
one FU visit after 36.68 ± 16.67 months in CN partici-
pants (n = 79) and 33.9 ± 16.07 months in CI (n = 94, p-
value = 0.256) showed CDRSoB changes of 0.241 ± 0.76
and 2.88 ± 3.62 in CN and CI participants respectively
(p-value < 0.001). For MMSE we observed a change of −
0.17 ± 1.16 in CN participants and of − 3.15 ± 5.60 in CI
patients (p-value < 0.001). In CN participants both
plasma NfL and p-tau181 levels positively correlated
with age (spearman’s rho = 0.602 and 0.249, respect-
ively), while in CI patients plasma NfL correlated with
age and years of education (rho = 0.363 and − 0.243, re-
spectively) and p-tau181 with APOE ε4 status (rho =
0.223). Neither plasma NfL nor plasma p-tau181 corre-
lated with Qalb. Furthermore, Nfl levels correlated with
CDR, CDRSoB, and MMSE scores (rho = 0.307, 0.44 and
− 0.295, respectively) in CI patients.
Associations of plasma NfL and p-tau181 levels with AD
Plasma NfL levels were significantly higher in CN partic-
ipants with cerebral AD pathology (as indicated by the
presence of an AD CSF profile) and in both AD and
non-AD CI patients when compared with CN non-AD
participants (Fig. 1a). Plasma p-tau181 levels were sig-
nificantly increased in CI participants with AD as com-
pared with CI non-AD patients and both AD and non-
AD CN participants (Fig. 1b). Hippocampal volume did
not show significant differences between AD and non-
AD subgroups in either CN or CI participants (data not
shown). Within the CI group, no significant difference
was observed for either Age, Sex or Years of education.
When considering the following covariates in a regres-
sion model, age, sex, years of education, and APOE ε4
status only p-tau181 levels remained associated with AD
pathology in CI participants (Fig. 2a). Applying back-
wards variable selection to both of these models identi-
fied age for CN participants and age, APOE ε4 status,
and p-tau181 levels in CI participants as independent
predictors of AD pathology (Fig. 2b). The addition of
plasma p-tau181 levels to a reference model to predict
the presence of AD pathology improved prediction ac-
curacy in CI participants (Fig. 2c, d, p-value = 0.048; sen-
sitivity: 0.8; specificity: 0.79, Delong’s ΔAUC = 0.042).
Using a plasma p-tau181 cutoff at 9.68 pg/ml improved
the prediction of AD (AUC = 0.869, p-value = 0.036;
Delong’s ΔAUC = 0.051) in CI participants. Using this
cutoff also improved the prediction of AD in the whole
cohort (AUC = 0.861, p-value = 0.012; Delong’s ΔAUC =
Table 1 Characteristics of the study cohort
CN (n = 91) CI (n = 127) p-value
Demographic and clinical characteristics
Sex, female (%) 64.4 53.9 0.12
Age (years), mean ± SD 68.53 ± 7.31 74 ± 6.6 < 0.001
Years of education (years), mean ± SD 13.02 ± 2.54 12.26 ± 2.78 0.04
CDR, mean ± SD 0 0.59 ± 0.26 < 0.001
CDRSoB, mean ± SD 0.01 ± 0.07 2.12 ± 2.14 < 0.001
MMSE, mean ± SD 28.59 ± 1.25 25.29 ± 3.83 < 0.001
Biochemical measures
APOE ε4, n (%) 18 (21.2) 50 (43.5) 0.001
QAlb, mean ± SD 5.45 ± 2.28 6.93 ± 3 0.002
CSF AD biomarkers < 0.001
Aβ1–42, pg/ml, mean ± SD 1030.62 ± 262.46 754.58 ± 287.32 < 0.001
Tau, pg/ml, mean ± SD 301.09 ± 175.95 493.04 ± 308.79 < 0.001
p-tau181, pg/ml, mean ± SD 57.74 ± 20.48 70.49 ± 29.77 < 0.001
Aβ1–42/Aβ1–40 0.07 ± 0.02 0.05 ± 0.02 < 0.001
MRI
Hippocampal volume 0.0046 ± 46E-5 0.0041 ± 57E-5 < 0.001
Plasma biomarkers
NfL, pg/ml, mean ± SD 17.61 ± 9.24 24.66 ± 11.66 < 0.001
p-tau181, pg/ml, mean ± SD 9.58 ± 7.09 14.78 ± 9.69 < 0.001
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Fig. 1 Plasma NfL and p-tau181 levels in the cohort. Boxplots of plasma NfL (a) and p-tau181 (b) concentrations in cognitively healthy
participants (CN) and patients with cognitive impairment (CI). Both groups were further stratified according to AD CSF biomarker profile. Mean
concentrations between pairs of groups were compared using T-tests. *, p-value < 0.05; ***, p-value < 0.001
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0.049). Plasma NfL levels did not contribute to improv-
ing the prediction of AD (Fig. 2d), nor did adding both
markers in combination (data not shown).
Associations of plasma NfL and p-tau181 with CSF
biomarkers of amyloid pathology, neuronal injury, and
tau hyperphosphorylation
In the whole cohort, both plasma NfL and p-tau181
levels correlated with all assessed AD CSF biomarkers
and with the hippocampal volume (data now shown). In
both groups, plasma NfL and plasma p-tau181 levels
were correlated (Table 2). In CN participants, plasma
Nfl levels correlated with those of CSF tau and p-tau181,
and plasma p-tau181 correlated with CSF p-tau181. In
CI participants, plasma NfL levels correlated with CSF
tau and hippocampal volume whereas plasma p-tau181
Fig. 2 Models for the prediction of AD. a-b Binomial logistic regression models with the presence of AD pathology as dependent variable along
with sex, age, years of education, APOE ε4 carrier status, plasma NfL and plasma p-tau181 levels, with no variable selection (a) or backwards
variable selection (b). Coefficients (B) and odds-ratio (Exp(B)) are shown. c ROC curves from predictive models of the presence of AD in CI
participants. The reference model (blue) and the reference model with p-tau-181 levels (red) are shown. The 0.5 AUC reference line is shown in
green. ROC curves for CN participants for either models are not shown. d AUC of ROC curves obtained by the reference model (Reference) and
after adding plasma NfL (+NFL) or p-tau181 levels (+PTAU) in both the CN and CI groups. *, p-value < 0.05
Table 2 Correlations (rho) of plasma NfL and plasma p-tau181
levels with other biomarkers
Plasma NfL Plasma p-tau181
rho p-value rho p-value
CN participants
CSF Aβ1–42 0.130 0.235 − 0.021 0.849
CSF Aβ1–42/Aβ1–40 −0.074 0.510 − 0.0173 0.128
CSF p-tau181 0.242 0.026 0.326 0.003
CSF tau 0.26 0.016 0.213 0.055
Plasma NfL 0.317 < 0.001
Plasma p-tau181 0.317 < 0.001
Hippocampal volume 0.027 0.817 0.023 0.849
CI participants
CSF Aβ1–42 −0.052 0.584 0.415 < 0.001
CSF Aβ1–42/Aβ1–40 −0.006 0.950 − 0.328 < 0.001
CSF p-tau181 0.148 0.116 0.417 < 0.001
CSF tau 0.233 0.013 0.496 < 0.001
Plasma NfL 0.336 < 0.001
Plasma p-tau181 0.336 < 0.001
Hippocampal volume − 0.349 0.002 −0.135 0.235
Table 3 Associations of plasma NfL and p-tau181 levels with
CDRSoB and MMSE change
ΔCDRSoB ΔMMSE
Variable Coeff. p-value Variable Coeff. p-value
CN NfL 0.386 0.001 NfL − 0.142 0.240
p-tau181 − 0.056 0.620 p-tau181 0.030 0.801
CI NfL 0.227 0.035 NfL − 0.145 0.230
p-tau181 0.252 0.020 p-tau181 − 0.293 0.017
Linear regression models with changes in CDRSoB (ΔCDRSoB) or MMSE
(ΔMMSE) at last follow-up as dependent variables with plasma NfL or p-tau181
levels. For each variable, standardized coefficients (Coeff.) and significance
are shown
Clark et al. Alzheimer's Research & Therapy           (2021) 13:65 Page 6 of 11
levels were correlated with all AD CSF biomarkers but
not hippocampal volume (Table 2).
Associations of plasma NfL and p-tau181 with disease
severity progression and cognitive decline
In CN participants, only NfL plasma levels were associ-
ated with changes in CDRSoB, while in the CI group
NfL levels were associated with changes in CDRSoB, and
p-tau181 levels were associated with changes in both
CDRSoB and MMSE (Table 3). After controlling for age,
sex, years of education, APOE ε4 status, baseline score,
and time to follow-up; the association of plasma NfL
levels with CDRSoB changes remained significant in CN
participants, as well as the association of p-tau181 with
MMSE change in CI participants (Fig. 3a). Applying
backwards selection to determine the best predictive
models identified plasma NfL as an independent pre-
dictor of changes in CDRSoB in CN participants and
plasma p-tau181 as an independent predictor of MMSE
changes in CI participants (Fig. 3b). Adding plasma p-
tau181 levels to a reference model improved the predic-
tion of a decline in global cognition in CI participants
(Fig. 3c, d, p-value = 0.0318; sensitivity: 0.88; specificity:
0.69, Delong’s ΔAUC = 0.051). Despite their association
with CDRSoB changes, plasma NfL levels did not con-
tribute to improve prediction of disease severity progres-
sion when compared with a reference model (data not
shown). Combinations of both plasma markers did not
improve this prediction either (data not shown).
Discussion
We have found increased plasma NfL levels in CN par-
ticipants with AD pathology, as compared with CN par-
ticipants without AD pathology. Regression analysis
found no associations between plasma NfL levels and
AD pathology, however. Plasma p-tau181 levels were
higher in the CI patients with AD and improved a model
for AD prediction in CI participants. Further, plasma
NfL levels were associated with clinical disease progres-
sion in the CN group while plasma p-tau181 levels were
associated with decline in global cognition in the CI
group. However, only plasma p-tau181 levels improved a
reference model to predict cognitive decline in CI partic-
ipants. Together, these results support the idea of
plasma NfL levels as being a marker of neurodegenera-
tion, but not specific for AD, and suggest plasma p-
tau181 levels could be used for both the diagnosis of AD
and the prediction of disease progression in memory
clinic patients.
Plasma NfL levels were higher in CN with AD, CI
non-AD, and CI with AD groups, when compared to
CN non-AD participants. Previous studies have reported
higher plasma NfL levels to be associated with AD de-
mentia [3–6]. These studies defined AD using clinical
Fig. 3 Models for the prediction of cognitive change. a-b Linear regression models with changes in cognition at last follow-up as a dependent
variable along with sex, age, years of education, APOE ε4 carrier status, Baseline cognitive score, time to follow-up plasma NfL and plasma p-
tau181 levels, with no variable selection (a) or backwards variable selection (b). Standardized coefficients, where the variances of dependent and
independent variables are equal to 1 (Coeff.) and p-values are shown. c ROC curves from predictive models of the presence of MMSE change in
CI participants. The reference model (blue) and the reference model with p-tau181 levels (red) are shown. The 0.5 AUC reference line is shown in
green. ROC curves for CN participants for either models are not shown. d AUC of ROC curves obtained by the reference model (Reference) and
after adding plasma NfL (+NFL) or plasma p-tau181 levels (+PTAU) in both the CN and CI groups. *, p-value < 0.05
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assessment only [23] and did not consider CSF bio-
markers for AD diagnosis. Accordingly, patients present-
ing clinically as AD dementia, but having cognitive
impairment due to other cerebral pathologies may have
been misdiagnosed and included, whereas our approach
considers cerebral pathology as measured by CSF bio-
markers. Additionally, we considered in our reference
model known diagnosis covariates, including APOE ε4
status. We found that plasma NfL levels were not associ-
ated with the presence of AD pathology in either the CN
or CI group. These results along with our finding of cor-
relations between NfL and CSF tau, but not CSF Aβ1–
42 and CSF Aβ42/Aβ40 ratio reinforce the role of NfL
as a marker for neuronal injury [2], although not in an
AD specific fashion as, in line with previous work, NfL
appears independent of amyloid pathology [24].
Previous studies found associations of elevated plasma
p-tau181 with amyloid positivity in participants with
normal cognition or with cognitive impairment [8, 11,
12]. A previous study found that combining plasma p-
tau181 levels with either CSF tau or p-tau181 increases
the predictive performance of clinically defined AD [25].
Another study that defined AD considering both amyl-
oid pathology and tau pathology reported results in line
to ours, i.e., elevated p-tau181 levels in AD and predict-
ive power in MCI and dementia participants [10]. The
addition of plasma p-tau181 levels to a reference model
including age, sex, years of education, and APOE ε4 sta-
tus significantly improved the prediction performance
for AD in CI patients. We observed a significant contri-
bution of plasma p-tau181 independently of APOE ε4 in
this model. Previous studies investigating the association
of plasma p-tau181 with AD either did not consider the
APOE genotype [12, 13], or they did not consider the ef-
fects of this factor independently of p-tau181 [9, 10].
Considering the APOE ε4 genotype as a covariate, we
found that plasma p-tau181 has an independent and sig-
nificant contribution to the prediction of AD in patients
with cognitive impairment. This finding indicates that
the combination of plasma p-tau181 and APOE ε4 geno-
type with clinical variables is superior to considering
APOE ε4 genotype and clinical variables only to diag-
nose AD in memory clinic patients with cognitive
impairment.
Together, our results indicate that plasma NfL levels
can be used to identify participants with normal cogni-
tion at increased risk of having cerebral AD pathology
and contributes to identifying neurodegeneration irre-
spective of the underlying cause. According to our find-
ings, plasma NfL does not contribute to improving
differential diagnosis of AD in memory clinic patients
with cognitive impairment. On the other hand, plasma
p-tau181 levels have an independent and significant con-
tribution to the prediction of the presence of cerebral
AD pathology and appear to be more specific than
plasma NfL levels for AD pathology. Therefore, plasma
p-tau181 may be more appropriate for differential diag-
nosis in memory clinic patients presenting with cogni-
tive impairment. Other studies using different
quantification methods [9, 26, 27] have also reported this
association between plasma p-tau181 levels and AD, fur-
ther supporting its usage as a blood-based biomarker of
AD. Importantly, neither plasma biomarker was corre-
lated to QAlb levels, indicating their levels are independ-
ent of blood-CSF barrier permeability.
The non-specificity of the association of plasma NfL
with AD is further shown by correlations of plasma NfL
with CSF tau levels, independently of cognitive status,
while only a weak correlation with CSF p-tau181 in CN,
and no correlation with CSF markers other than CSF tau
were present in CI. In a previous study, plasma NfL was
not associated with any CSF biomarker in CN partici-
pants and AD dementia patients, but in MCI partici-
pants it was associated with CSF Aβ1–42 and CSF tau
[3]. Plasma NfL levels have been previously correlated to
amyloid load assessed by PET scan in cognitively normal
participants [28]. This suggests AD pathology might be
the main cause of neuronal injury and therefore NfL in-
crease in CN participants, while in a majority of patients
in the CI group neuronal injury might be caused by
other pathologies, rendering NfL inefficient for differen-
tial diagnosis in this later group. Conversely, plasma p-
tau181 levels correlated with CSF p-tau181 in CN partic-
ipants and with all CSF biomarkers in CI participants,
reinforcing its role as a biomarker candidate useful for
differential diagnosis of AD.
In both CN and CI groups, higher plasma NfL baseline
levels were associated with more rapid increase in dis-
ease severity as indicated by CDRSoB change at follow-
up. After controlling for possible confounders only the
association of plasma NfL levels with CDRSoB changes
in CN participants remained significant. Previous studies
have reported plasma NfL levels to correlate with base-
line cognition [3–7, 29–31]. Of these studies, only two
considered both CDR and MMSE scores [4, 7], and a
single study reported a correlation of plasma NfL levels
with longitudinal MMSE change in cognitively impaired
participants [3]. In line with previous reports [4–6], in
CI patients higher NfL was associated with more marked
increase in clinical disease severity over time. When
added to a reference model based on clinical variables
and the APOE ε4 status, plasma NfL did not significantly
improve the prediction of severity progression at follow-
up visit, however. Since NfL can be associated with
neuronal injury of multiple aetiologies rather than with a
specific pathological mechanism, elevated levels are indi-
cative of multiple potential outcomes, rendering it in-
appropriate for modeling. Overall, our results suggest
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plasma NfL may be useful as a blood-based marker to
identify individuals at high risk of cognitive decline
among cognitively normal individuals.
We found higher plasma p-tau181 levels to be associ-
ated with more rapid increase in disease severity as well
as with more marked decline in global cognition as
assessed by changes in MMSE. Adding plasma p-tau181
levels to a reference model including age, sex, years of
education, APOE ε4 status, baseline MMSE, and time to
follow-up, significantly improved the prediction of de-
cline in global cognition in CI participants. While the as-
sociation of high levels of plasma p-tau181 with
cognitive decline has been previously observed in MCI
patients [13], we show here the added value of this
plasma marker to predict cognitive decline when com-
bined with other non-invasive measures. While these
findings remain to be confirmed in an independent co-
hort, they suggest the utility of plasma p-tau181 in clin-
ical practice as a blood-based prognostic biomarker for
cognitive decline, in particular in patients with cognitive
impairment.
Limitations
A limitation of this study is the relatively small number
of included participants with dementia, preventing us to
specifically address the performance of the plasma bio-
marker candidates in this subgroup. Our work does
however benefit from the inclusion of both elderly par-
ticipants with normal cognition and memory clinic
patients with cognitive impairment, allowing the assess-
ment of differential diagnosis utility. Furthermore, we
used established CSF biomarkers of cerebral AD path-
ology to define AD at both the asymptomatic and the
clinical stage, enabling to address relationships to cere-
bral pathology while ensuring cognitive impairment due
to other cerebral pathologies was not misdiagnosed as
AD. Additionally, we have considered multiple covari-
ates in this study, therefore assessing the specific clinical
relevance of plasma NfL and p-tau181 levels.
Conclusions
We have investigated the associations of plasma NfL and
p-tau181 levels with CSF biomarkers of amyloid, neur-
onal injury, and tau pathology, and the predictive per-
formance of the plasma marker candidates for cerebral
AD pathology and cognitive decline. Our results suggest
that plasma NfL may be useful as a blood-based marker
to identify cognitively normal individuals at risk of cog-
nitive decline. Plasma p-tau181 levels can serve as a pre-
dictive blood-based biomarker of both AD pathology
and cognitive decline, but its performances depend on
whether it is used in cognitively normal older individuals
or in patients with cognitive impairment. While these
findings need further validation in independent samples
before use in clinical practice, they show the potential
utility of blood-based biomarkers in both older individ-
uals with normal cognition and memory clinic patients
with cognitive impairment.
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